Previous studies have emphasized significant variation in the management of muscle invasive bladder cancer (MIBC) with sub-optimal outcomes for those outside of high-volume, specialized centers. Optimization of surgical care delivery for patients with MIBC in the general population includes the development and implementation of markers of quality of care utilizing reliable and valid indicators.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Several important findings have emerged from our population-based study in Ontario, Canada. First, we have observed a high rate of transfusion in routine clinical practice. Secondly, we demonstrate that PBT is associated with multiple patient- and disease-related factors, as well as provider volume. Thirdly, PBT appears to be strongly associated with early morbidity and mortality that would appear to confirm that PBT is a marker of a more complex peri-operative course. Finally, receiving a PBT was associated with worse 5-year OS and CSS in routine clinical care, despite controlling for important confounders. These findings suggest to us that documentation of allogenic blood transfusion during an admission for cystectomy is indeed a valid quality indicator of surgical care for patients with MIBC.
Clearly, RC is a technically challenging undertaking. As a result, intra-operative blood loss and, therefore, subsequent RBC transfusions, are robust quality indicators because they are ‘specific and measurable elements of practice that can be used to assess quality of care’. Moreover, this element of care is also modifiable because it is often surgeon or anaesthesiologist determined. As a result, it is one of the few modifiable factors that we have available for both short- and long-term outcomes. The need for a transfusion can also be altered by technical modifications such as minimizing blunt dissection, ensuring intra-operative haemostasis, maintaining normothermia and of course utilization of increased intra-abdominal pressures during laparoscopy. Non-technical approaches to reduce blood loss are also helpful and include pre-operative improvement of haemoglobin levels (iron and erythropoietin), minimizing redundant blood tests (pre- and post-operative), reducing central venous pressures, employing blood cell salvage devices and following evidence-based guidelines for lower transfusion triggers.
Our study confirms that administrative documentation of transfusion was associated with both early outcomes as well as long-term survival and importantly this association is persistent despite adjustment for provider volumes. These data suggest that PBT may be a valid indicator of surgical care of MIBC in the general population and reporting of transfusion rates should be considered by hospitals or regional cancer control bodies.
Written By: D. Robert Siemens, MD, FRCSC, Department of Urology, Queen’s University, Kingston, Ontario, Canada
Read the Abstract